Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

Trial Details

NCT ID

NCT06151080

Phase

PHASE2

Sponsor

The First Affiliated Hospital of Xiamen University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Lenalidomide combined with G-CHOP (LO CHOP)

Locations (sample)

• Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

• Age: 18-70 years old, gender is not limited;
• According to the REAL/WHO classification, the newly diagnosed diffuse large b-cell lymphoma with follicular lymphoma (CDLBCL-FL): the same lymph no…
• Using the Lugano 2014 lymphoma response evaluation criteria, there must be at least one measurable or evaluable lesion: PET/CT can evaluate the les…
• Left ventricular ejection fraction (LVEF) was less than 45%

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.